Ligand Pharmaceuticals enters into a global license agreement with Emergent BioSolutions under which Emergent will use Ligand’s OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies.
{iframe}http://seekingalpha.com/news/3029176-emergent-bio-licenses-ligand-pharmas-technology-to-augment-its-discovery-of-new-antibodies#email_link{/iframe}